-
No water
Selectively adhesive - mucoadhesion and dermal adhesion
Different viscosities based on desired end use
Universal carrier - molecule agnostic
Dermal release
Rapid release
-
Scalable - rapidly scale to commercial manufacturing
Economic - low cost of base components
Potential white label manufacturing
Patent protected
FDA and CE cleared products
-
Multiple delivery pathways - dermal, oral, mucosal delivery options.
Oral mucosal - does not require swallowing - can be given to patients who are unable to swallow - human or animal
Lip application - as a new therapeutic release options such as a balm
Teeth/gums - gels, liquids, self or professionally applied
Nasal passages - gels
Skin/dermis - alternative delivery of medications, skin care
Vaginal - suppositories
Rectal - suppositories
Wound care - deliver antibiotics, protection of wounds
Nail beds/sterile matrix - anti-fungal applications
Key Characteristics
Inspired
Material Strategies
VIZCID TECHNOLOGY CREATED BY
Inspired Material Strategies (IMS) was formed with the goal of expanding a new platform technology into diverse verticals that leverage the features of the unique carrier. A key benefit of working with IMS is our small, nimble team, with deep expertise, which allows for rapid prototyping of your molecule into the Vizcid carrier. The IMS team will work with you to customize a variety of end products, for optimal release, adhesion, and usability of the material.
IMS’ business model is to license the patented Vizcid technology in discrete fields allowing its unique properties to be exploited by industry experts in the creation of new product formulations to your specifications and to work with industry to solve delivery problems for new or existing technologies in a de-risked setting using carriers that have a long history of safe regulatory use.
Our Team
We are a unique team of professionals, with decades of development of products that have successfully launched into worldwide markets.
-
Dr. Latta is a board certified dentist and has decades of experience as an inventor and also in product development of dental products and delivery of active drug products into the mouth. His work has included multiple years in product development for a large dental products company, as well as the past 5+ years in development of Vizcid. He is a named inventor on dozens of granted US and worldwide patents.
-
Dr. Stibich, like the other team members, has numerous successes under his belt, and has overseen, as a founder, CEO and CSO the development and expansion of product lines in multiple market segments. Dr. Stibich is a named inventor on nearly 150 granted patents, and his expertise in developing and executing research plans to move products through early commercial and regulatory hurdles is critical. He has received NIH grants for commercialization and his products have received awards for commercialization from the VA and the FLC (Federal Laboratory Consortium).
-
Ms. Daug, whose past experiences include serving as the Manager of New Venture Development at Thomas Jefferson University, focuses on taking nascent technologies and moving them forward to commercialization. She has successfully partnered with numerous companies to support fundraising efforts and move products from inception through to growth and commercialization phases.
-
Mr. Vos Strache has partnered with dozens of pharmaceutical and medical device companies to develop strategic intellectual property portfolios, with a goal on creating strategic assets. His primary focus is to take concept stage ideas and develop them with necessary patent protections to increase asset value. Numerous of the companies Mr. Vos Strache has worked with have raised Series A rounds, and otherwise exited into commercial applications, including multiple companies that have applied for an obtained regulatory approval in the US and worldwide, or in nutraceutical applications.